Nasdaq
$7.72▼ 2.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $46.2MShares out 6.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.2After-hours26.10.03 05:334Ownership#●●●
Xilio Therapeutics, Inc.
Insider Yariv Houvras of Xilio Therapeutics, Inc. reported a change in beneficial ownership of securities effective October 1, 2026. This filing provides the details of the insider transaction as required by Form 4.…more
$7.72-2.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:313Ownership
Xilio Therapeutics, Inc.
Yariv Houvras of Xilio Therapeutics has executed a Power of Attorney to authorize designated representatives to handle SEC filings and manage the company's EDGAR account. This document grants the appointed attorneys-in-fact the authority to prepare and submit necessary SEC forms on behalf of the applicant.…more
$7.72-2.03%vs prev closeView filingShare - 8.12Pre-market26.08.12 20:45S-8Offering
Xilio Therapeutics, Inc.
On August 12, 2026, Xilio Therapeutics filed a Form S-8 to register an additional 373,555 shares of common stock for its 'Third Amended and Restated 2022 Inducement Stock Incentive Plan.' This registration is intended for employee stock-based compensation, which may result in dilution for existing shareholders.…more
$7.72-2.03%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.2After-hours26.10.03 05:30#●●●#●●●
Xilio Therapeutics Grants Stock Options to New CMO and Employees
Xilio Therapeutics has granted stock options for a total of 205,895 shares to its newly appointed Chief Medical Officer and other new employees. This is a standard compensation practice for talent acquisition and does not directly impact the company's financial performance.…more
$7.72-2.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.28Pre-market26.09.28 20:30
●●●●●●●● ●●●●● ●●●●●●
Xilio Therapeutics has appointed Dr. Yariv Houvras, an expert in clinical development and immuno-oncology, as its new Chief Medical Officer. This leadership addition aims to accelerate the clinical advancement of the company's lead pipeline candidate, XTX501.…more
$7.72-2.03%vs prev close - 9.2After-hours26.09.03 05:30
●●●●●●●● ●●●●● ●●●●●●
Xilio Therapeutics has granted stock options to two new employees as an inducement for their employment under Nasdaq listing rules. This is a standard corporate practice for talent acquisition and does not have a material impact on the company's valuation.…more
$7.72-2.03%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report